Related Experiment Video
Updated: Feb 15, 2026

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
Published on: January 5, 2018
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Chiara Ambrogio1, Jens Köhler1, Zhi-Wei Zhou2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Wild-type KRAS inhibits tumor growth by forming dimers with mutant KRAS, conferring MEK inhibitor resistance in lung cancer. Disrupting KRAS dimerization may offer a new therapeutic strategy for KRAS-mutant cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- The role of wild-type KRAS in suppressing oncogenic KRAS activity in cancers like lung adenocarcinoma (LUAD) remains unclear.
- Understanding this mechanism is crucial for developing effective cancer therapies.
Purpose of the Study:
- To elucidate the mechanism by which wild-type KRAS influences oncogenic KRAS activity.
- To investigate the role of KRAS dimerization in LUAD tumor cell fitness and resistance to MEK inhibition.
- To explore the therapeutic potential of targeting KRAS dimerization.
Main Methods:
- Utilized a genetically inducible model of KRAS loss of heterozygosity (LOH).
- Investigated KRAS dimerization using in vitro and in vivo assays.
- Employed KRAS D154Q mutant to disrupt dimerization at the α4-α5 interface.
Main Results:
- KRAS dimerization mediates wild-type KRAS-dependent fitness in KRAS-mutant LUAD cells.
- KRAS dimerization underlies resistance to MEK inhibition in these cells.
- Disruption of KRAS dimerization via KRAS D154Q abrogated these effects, impacting oncogenic activity.
Conclusions:
- KRAS dimerization is a key mechanism for wild-type KRAS-mediated growth inhibition and MEK inhibitor resistance.
- KRAS dimerization plays a critical role in the oncogenic activity of mutant KRAS.
- Targeting KRAS dimerization presents a promising therapeutic strategy for KRAS-mutant cancers.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Impact of Groups on Groups
Impact
When particles with different initial velocities collide, they induce deformation by applying equal and opposite impulses. At the point of maximum deformation, the particles move together with...
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
Impact of Groups on Individuals

